B.Braun Patent-Cliff Exposure & CMS Drug Spending Portfolio
B.Braun (US): 13 reconciled FDA prescription therapies, $37.8M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 13 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $37.8M |
| 2024 Medicare Part D Spend | $5.1M |
| 2024 Medicaid Spend | $32.8M |
| California HCAI SB 17 Filings | 5 WAC filings (max 26.6% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for B. Braun Medical across sibling Meru public-data platforms.